EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation
- Author
- TROWE, Torsten1 ; BOUKOUVALA, Sotiria1 ; VYSOTSKAIA, Valentina1 ; JING PING YANG1 ; GERRITSEN, Mary E1 ; MATTHEWS, David J1 ; LAMB, Peter1 ; HEUER, Timothy S1 ; CALKINS, Keith1 ; CUTLER, Richard E1 ; FONG, Ryan1 ; FUNKE, Roel1 ; GENDREAU, Steven B1 ; KIM, Yong D1 ; MILLER, Nicole1 ; WOOLFREY, John R1
[1] Exelixis, Inc, South San Francisco, California, United States - Source
Clinical cancer research. 2008, Vol 14, Num 8, pp 2465-2475, 11 p ; ref : 55 ref
- ISSN
- 1078-0432
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- American Association for Cancer Research, Philadelphia, PA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Anticancéreux Gène erbB2 Gène onc cellulaire Lapatinib Mutation Protooncogène Résistance Transformation maligne Récepteur HER2 Enzyme Inhibiteur de la tyrosine kinase Inhibiteur enzyme Protein-tyrosine kinase Transferases
- Keyword (en)
- Antineoplastic agent erbB2 Gene C-Onc gene Lapatinib Mutation Protooncogene Resistance Malignant transformation Human Epidermal growth factor Receptor 2 Enzyme Tyrosine kinase inhibitor Enzyme inhibitor Protein-tyrosine kinase Transferases
- Keyword (es)
- Anticanceroso Gen erbB2 Gen onc celular Lapatinib Mutación Protooncogen Resistencia Transformación maligna Enzima Inhibidor tyrosine kinase Inhibidor enzima Protein-tyrosine kinase Transferases
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 20310162
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1158/1078-0432.CCR-07-4367 
https://dx.doi.org/10.1158/1078-0432.CCR-07-4367
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-07-4367\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:107:\"EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"14\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"2465\";s:8:\"\u0000*\u0000epage\";s:4:\"2475\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"TROWE\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Torsten\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:19:\"BOUKOUVALA, Sotiria\";i:1;s:21:\"VYSOTSKAIA, Valentina\";i:2;s:14:\"JING PING YANG\";i:3;s:17:\"GERRITSEN, Mary E\";i:4;s:17:\"MATTHEWS, David J\";i:5;s:11:\"LAMB, Peter\";i:6;s:16:\"HEUER, Timothy S\";i:7;s:14:\"CALKINS, Keith\";i:8;s:17:\"CUTLER, Richard E\";i:9;s:10:\"FONG, Ryan\";i:10;s:11:\"FUNKE, Roel\";i:11;s:18:\"GENDREAU, Steven B\";i:12;s:11:\"KIM, Yong D\";i:13;s:14:\"MILLER, Nicole\";i:14;s:16:\"WOOLFREY, John R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:107:\"EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-07-4367\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:107:\"EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"14\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"2465\";s:8:\"\u0000*\u0000epage\";s:4:\"2475\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"TROWE\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Torsten\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:19:\"BOUKOUVALA, Sotiria\";i:1;s:21:\"VYSOTSKAIA, Valentina\";i:2;s:14:\"JING PING YANG\";i:3;s:17:\"GERRITSEN, Mary E\";i:4;s:17:\"MATTHEWS, David J\";i:5;s:11:\"LAMB, Peter\";i:6;s:16:\"HEUER, Timothy S\";i:7;s:14:\"CALKINS, Keith\";i:8;s:17:\"CUTLER, Richard E\";i:9;s:10:\"FONG, Ryan\";i:10;s:11:\"FUNKE, Roel\";i:11;s:18:\"GENDREAU, Steven B\";i:12;s:11:\"KIM, Yong D\";i:13;s:14:\"MILLER, Nicole\";i:14;s:16:\"WOOLFREY, John R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:107:\"EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-07-4367\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-07-4367\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:107:\"EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"14\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"2465\";s:8:\"\u0000*\u0000epage\";s:4:\"2475\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"TROWE\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Torsten\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:19:\"BOUKOUVALA, Sotiria\";i:1;s:21:\"VYSOTSKAIA, Valentina\";i:2;s:14:\"JING PING YANG\";i:3;s:17:\"GERRITSEN, Mary E\";i:4;s:17:\"MATTHEWS, David J\";i:5;s:11:\"LAMB, Peter\";i:6;s:16:\"HEUER, Timothy S\";i:7;s:14:\"CALKINS, Keith\";i:8;s:17:\"CUTLER, Richard E\";i:9;s:10:\"FONG, Ryan\";i:10;s:11:\"FUNKE, Roel\";i:11;s:18:\"GENDREAU, Steven B\";i:12;s:11:\"KIM, Yong D\";i:13;s:14:\"MILLER, Nicole\";i:14;s:16:\"WOOLFREY, John R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:107:\"EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-07-4367\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:107:\"EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"14\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"2465\";s:8:\"\u0000*\u0000epage\";s:4:\"2475\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"TROWE\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Torsten\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:19:\"BOUKOUVALA, Sotiria\";i:1;s:21:\"VYSOTSKAIA, Valentina\";i:2;s:14:\"JING PING YANG\";i:3;s:17:\"GERRITSEN, Mary E\";i:4;s:17:\"MATTHEWS, David J\";i:5;s:11:\"LAMB, Peter\";i:6;s:16:\"HEUER, Timothy S\";i:7;s:14:\"CALKINS, Keith\";i:8;s:17:\"CUTLER, Richard E\";i:9;s:10:\"FONG, Ryan\";i:10;s:11:\"FUNKE, Roel\";i:11;s:18:\"GENDREAU, Steven B\";i:12;s:11:\"KIM, Yong D\";i:13;s:14:\"MILLER, Nicole\";i:14;s:16:\"WOOLFREY, John R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:107:\"EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
